Reni Benjamin has given his Buy rating due to a combination of factors that highlight Iovance Biotherapeutics’ promising investment potential. The company has demonstrated strong performance ...
Funding to support clinical proof-of-concept for the lead program, VIPER-101 PHILADELPHIA, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Vittoria Biotherapeutics, Inc., a clinical-stage immunotherapy company ...
SAN DIEGO, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback